CONTROLLED TRIAL OF PREDNISONE AND AZATHIOPRINE IN ACTIVE CHRONIC HEPATITIS
References (18)
- et al.
Am. J. Med.
(1970) - et al.
Gastroenterology
(1972) - et al.
Am. J. Med.
(1964) - et al.
Lancet
(1968) - et al.
Lancet
(1971) - et al.
Lancet
(1970) - et al.
Jl Med.
(1971) - et al.
Australas. Ann. Med.
(1967)
There are more references available in the full text version of this article.
Cited by (383)
Treatment of Autoimmune Hepatitis
2024, Clinics in Liver DiseaseCurrent paradigm and treatment options for autoimmune hepatitis
2023, Comprehensive Guide to Hepatitis AdvancesLong-term results of mycophenolate mofetil vs. azathioprine use in individuals with autoimmune hepatitis
2022, JHEP ReportsCitation Excerpt :Corticosteroids alone or in combination with azathioprine (AZA) is recommended as the standard first-line treatment option. However, this recommendation is still based on trials conducted in the past 5 decades with the last published 26 years ago.5–10 The aims of treatment are to achieve complete biochemical response (CBR; normal IgG and aminotransferases) and remission of the disease (modified hepatitis activity index [mHAI] <4).
Budesonide in the first line treatment of patients with autoimmune hepatitis
2022, Gastroenterologia y HepatologiaA collaborative integrative and Ayurvedic approach to cirrhosis in the setting of autoantibody negative autoimmune hepatitis: a case report
2022, Advances in Integrative MedicineMycophenolate mofetil as second line treatment in autoimmune hepatitis – A retrospective single center analysis
2022, Journal of Translational Autoimmunity
Copyright © 1973 Published by Elsevier Ltd.